ClinSeq started in April 2013 and has delivered cutting edge research and initiated projects for implementation of genomics based diagnostics in clinical care.
Cutting edge research:
Evaluation of intraprostatic tumor heterogeneity by profiling multiple tumor foci in prostate cancer patients.
Development of new methods to measure circulating tumor DNA for patients with low-grade, primary cancers (work in progress)
Validation of prognostic models in large population based cohorts (work in progress)
Clinical implementation projects:
Breast cancer diagnostics based on ClinSeq to be implemented in Stockholm by fall 2014. Benchmarking with routine diagnosis is currently undertaken.
AML diagnostics based on ClinSeq to be implemented on a national level by fall 2014. Benchmarking with routine diagnosis is currently undertaken
Colorectal cancer study based on ClinSeq is currently in preparation. This is a nation-wide study where patients with perturbed PI3K signaling will be randomized between placebo and ASA. Validation of FFPE versus snap-frozen samples is currently being undertaken.
Discussions on starting clinical implementation programs are being held with leading clinical researchers in several other cancer diagnostics.